Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Trends in kinase drug discovery: targets, indications and inhibitor design
The FDA approval of imatinib in 2001 was a breakthrough in molecularly targeted cancer
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …
therapy and heralded the emergence of kinase inhibitors as a key drug class in the oncology …
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
M He, C Cao, Z Ni, Y Liu, P Song, S Hao, Y He… - Signal transduction and …, 2022 - nature.com
Abstract PROteolysis TArgeting Chimeras (PROTACs) technology is a new protein-
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …
degradation strategy that has emerged in recent years. It uses bifunctional small molecules …
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …
C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive …
NTRK fusion-positive cancers and TRK inhibitor therapy
N TRK gene fusions involving either NTRK1, NTRK2 or NTRK3 (encoding the neurotrophin
receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and …
receptors TRKA, TRKB and TRKC, respectively) are oncogenic drivers of various adult and …
[HTML][HTML] NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls
JP Solomon, I Linkov, A Rosado, K Mullaney… - Modern pathology, 2020 - Elsevier
With the FDA approval of larotrectinib, NTRK fusion assessment has recently become a
standard part of management for patients with locally advanced or metastatic cancers …
standard part of management for patients with locally advanced or metastatic cancers …
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Background Gene fusions involving NTRK1, NTRK2, or NTRK3 (TRK fusions) are found in a
broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small …
broad range of paediatric and adult malignancies. Larotrectinib, a highly selective small …
The role of brain derived neurotrophic factor in central nervous system
Brain derived neurotrophic factor (BDNF) has multiple biological functions which are
mediated by the activation of two receptors, tropomyosin receptor kinase B (TrkB) receptor …
mediated by the activation of two receptors, tropomyosin receptor kinase B (TrkB) receptor …
[HTML][HTML] NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
The tropomyosin receptor kinase (Trk) receptor family comprises 3 transmembrane proteins
referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the …
referred to as Trk A, B and C (TrkA, TrkB and TrkC) receptors that are encoded by the …
[HTML][HTML] Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer
The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by
NTRK genes and have a role in the development and normal functioning of the nervous …
NTRK genes and have a role in the development and normal functioning of the nervous …
Neurobiology of local and intercellular BDNF signaling
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family of secreted
proteins. Signaling cascades induced by BDNF and its receptor, the receptor tyrosine kinase …
proteins. Signaling cascades induced by BDNF and its receptor, the receptor tyrosine kinase …